Repligen (NASDAQ:RGEN) Shares Gap Down – Here’s What Happened

Repligen Corporation (NASDAQ:RGEN) shares gapped down before the market opened on Tuesday . The stock had previously closed at $135.40, but opened at $122.28. Repligen shares last traded at $135.75, with a volume of 518,745 shares traded.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Jefferies Financial Group set a $160.00 target price on Repligen and gave the stock a “hold” rating in a research note on Tuesday, October 28th. Weiss Ratings raised shares of Repligen from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, February 17th. UBS Group raised their price objective on shares of Repligen from $190.00 to $200.00 and gave the company a “buy” rating in a research note on Friday, January 16th. Wall Street Zen raised shares of Repligen from a “hold” rating to a “buy” rating in a research note on Saturday, February 7th. Finally, Canaccord Genuity Group raised their price target on shares of Repligen from $150.00 to $165.00 and gave the company a “hold” rating in a research report on Wednesday, October 29th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, Repligen currently has a consensus rating of “Moderate Buy” and a consensus target price of $177.92.

Repligen Price Performance

The firm has a market capitalization of $7.66 billion, a price-to-earnings ratio of 6,813.66, a price-to-earnings-growth ratio of 2.48 and a beta of 1.13. The stock’s fifty day moving average price is $156.30 and its two-hundred day moving average price is $146.71. The company has a current ratio of 8.36, a quick ratio of 7.14 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last posted its earnings results on Tuesday, February 24th. The biotechnology company reported $0.49 EPS for the quarter, beating the consensus estimate of $0.44 by $0.05. The firm had revenue of $197.91 million for the quarter, compared to analyst estimates of $192.23 million. Repligen had a return on equity of 4.66% and a net margin of 0.25%.Repligen’s revenue for the quarter was up 18.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.44 earnings per share. Repligen has set its FY 2026 guidance at 1.930-2.010 EPS. Equities research analysts expect that Repligen Corporation will post 1.72 EPS for the current year.

Insiders Place Their Bets

In other Repligen news, Director Karen A. Dawes sold 275 shares of the stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $161.00, for a total value of $44,275.00. Following the transaction, the director directly owned 91,821 shares in the company, valued at $14,783,181. This represents a 0.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.20% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Bayforest Capital Ltd purchased a new stake in Repligen in the fourth quarter valued at $32,000. Rachor Investment Advisory Services LLC purchased a new stake in shares of Repligen in the 4th quarter valued at about $33,000. Measured Wealth Private Client Group LLC acquired a new stake in shares of Repligen in the 3rd quarter valued at about $29,000. Los Angeles Capital Management LLC purchased a new position in Repligen during the 4th quarter worth approximately $36,000. Finally, Hantz Financial Services Inc. grew its stake in Repligen by 2,663.6% during the 2nd quarter. Hantz Financial Services Inc. now owns 304 shares of the biotechnology company’s stock worth $38,000 after buying an additional 293 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.